As Mr. Keon has already stated, the supply is controlled right to the point of pharmacy, at which point the dispensing decision is made.
I will point out that the generic market share of total sales of this compound is less than 5%, based on annual numbers that Mr. Keon showed me at lunchtime.
It seems to me that an element of better prevention, better treatment, and better control is needed.